In 1989, recombinant human erythropoietin (EPO) was approved for use in dialysis‐associated anemia, yet 3 years later only 60% of patients on dialysis were being treated to target hemoglobin (Hb) concentrations and many not at all. Here, EPO is linked to anemia.